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ORIGINAL ARTICLE
Combined Analysis of Phase I and Phase II Data to
Enhance the Power of Pharmacogenetic Tests
A Tessier1,2,3*, J Bertrand4, M Chenel3 and E Comets1,2,5
We show through a simulation study how the joint analysis of data from phase I and phase II studies enhances the power of
pharmacogenetic tests in pharmacokinetic (PK) studies. PK profiles were simulated under different designs along with 176
genetic markers. The null scenarios assumed no genetic effect, while under the alternative scenarios, drug clearance was
associated with six genetic markers randomly sampled in each simulated dataset. We compared penalized regression Lasso
and stepwise procedures to detect the associations between empirical Bayes estimates of clearance, estimated by nonlinear
mixed effects models, and genetic variants. Combining data from phase I and phase II studies, even if sparse, increases the
power to identify the associations between genetics and PK due to the larger sample size. Design optimization brings a
further improvement, and we highlight a direct relationship between g-shrinkage and loss of genetic signal.
CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 123–131; doi:10.1002/psp4.12054; published online 14 March 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  Most pharmacogenetic analyses in pharmacokinetic stud-
ies recently published included a limited number of subjects (fewer than 50). Previous simulations showed that such
sample sizes result in a low probability to detect polymorphisms. But with large numbers of subjects, extensive pharma-
cokinetic information is difficult to obtain in drug development. • WHAT QUESTION DID THIS STUDY ADDRESS? 
This simulation study explored realistic ways to increase the amount of information by combining rich phase I data and
sparse phase II data, and optimizing such sparse designs. • WHAT THIS STUDY ADDS TO OUR KNOWLEDGE  This
study shows that even sparse data from phase II allow a marked improvement in the probability to detect genetic variants
when combined with rich data from phase I, even more when sparse designs are optimized. • HOW THIS MIGHT
CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS  The pharmacogenetic analyses should be planned
later in drug development to take advantage of larger sample sizes by combining data that would increase the power to
detect genetic effects.
Studying the sources of the variability observed in drug
response facilitates individualization of prescription. One of
the sources of variability in drugs’ pharmacokinetics (PK)1
is the variation in activity of enzymes and transporters
involved in the drug absorption, distribution, metabolism, or
elimination. Pharmacogenetics2 studies the genetic compo-
nent of interindividual variability (IIV) observed in PK to
identify populations at risk of treatment inefficacy or
adverse effects.3 Single nucleotide polymorphisms (SNPs)
are the genetic variants most frequently studied in pharma-
cogenetics and screened more and more often in clinical
studies.
Genetic data offer some unique challenges, in particular
because they may lead to a very unbalanced number of
subjects, which impacts the power of tests in pharmacoge-
netic analyses.4,5 In a previous simulation work, we showed
that typical phase I studies have low power to detect
genetic effects because of the limited sample size.6 On the
other hand, phase I studies generally provide good quality
PK information, allowing characterization of the PK profile
of the drug. We showed that from the different approaches
used at this stage to estimate PK parameters, nonlinear
mixed effects models (NLMEM)7 could be considerably
more powerful than noncompartmental analyses (NCA)8 for
complex PK models.6 Our simulations also showed that
increasing the sample size, as in phase II studies, would
improve the power to detect genetic variants. However,
sparse designs typically used in phase II may result in
biased estimations for empirical Bayes estimates (EBE)9
used in a generalized additive model (GAM) covariate anal-
ysis procedure.10
To increase the detection of genetic covariates, one way
could be to combine for the analysis data from a study col-
lected with a rich design, as expected in phase I, with
sparser, but still informative, data from a phase II study.
In the present work we propose practical designs involv-
ing phase I and phase II data, and we quantify through sim-
ulations their ability to detect genetic associations with PK.
A motivating example was provided by IRIS (Institut de
Recherches Servier), a pharmaceutical industry, to gener-
ate realistic genetic and PK data. We compared two associ-
ation methods, a penalized regression method and a
stepwise procedure.6
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MATERIALS AND METHODS
Simulation study
Figure 1 presents the framework of the simulation study,
which was designed based on PK data from drug S (IRIS)
collected in 78 subjects from three phase I clinical stud-
ies.11 All subjects were genotyped at baseline using a DNA
microarray developed by IRIS of 176 SNPs known for being
involved in the PK of drugs. These 176 polymorphisms
were matched to a reference Hapmap panel (Hapmap 3,
release 2) for a Caucasian population12 and we used the
Hapgen2 software13 to simulate genetic variants retaining
their frequencies and the correlations between polymor-
phisms found in the human genome (see details in Supple-
mentary Material, Supplementary Figures S1–S3).
PK profiles were simulated with a two-compartment
model with dose-dependent double absorption (Supple-
mentary Figure S4), with the parameters in Table 1, under
two conditions: 1) no gene effect (H0); 2) gene effect on
clearance CL (H1). Under H1, six SNPs were drawn ran-
domly without physiological assumptions or prior knowl-
edge, and assumed to explain in total 30% of the IIV on CL
through the following additive genetic model on the log-
transformed CL:
log CLsimið Þ5log lCLð Þ1
X6
k51
bk3SNPik1giCL (1)
where CLsimi is the simulated individual clearance, lCL the
typical clearance, bk the effect size associated to the vari-
ant allele of SNPik , and giCL the interindividual random effect
for clearance of subject i . Causal SNPs were different from
one dataset to another. Assuming an additive genetic
model, genotypes take values 0, 1, or 2, reflecting the num-
ber of mutated alleles. We chose this model to simplify the
simulations but dominant or recessive genetic models could
be easily simulated by changing genotype values. bk was
computed as a function of the coefficient of genetic compo-
nent (RGCk , the percentage of the interindividual variability
in CL explained by the SNP) and the minor allele fraction
(pk ), as follows:
bk5
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where x2CL is the variance of interindividual random effects
on CL due to nongenetic sources. RGCk was respectively
equal to 1, 2, 3, 5, 7 and 12% for the six causal variants14
to mimic a multifactorial genetic effect. Then under H0, x2
CL50:06 (as in Table 1), while under H1 30% of the var-
iance is explained by the genetics so that x2CL50:04
(example on the magnitude of simulated effect sizes is
available in Supplementary Table S1).
The simulated datasets were then fitted with the base
model without genetic covariates. Individual clearance esti-
mates (EBECLi ) were estimated and all associations with
the 176 simulated polymorphisms were tested assuming a
linear relation without reestimating model parameters, as in
a GAM analysis.10
We compared two association methods to detect gene
effects. Lasso15 is a multivariate penalized regression
which simultaneously estimates effect size coefficients
and selects variants by setting a large number of coeffi-
cients to 0. The penalty is set by a tuning parameter (n)
which depends on a, the type I error per test, and the
number of subjects16,17 (Figure 1). Alternatively, in
practice the penalty can be determined through permu-
tation or cross-validation methods, which are more time-
consuming. A stepwise procedure includes relationships
one-by-one depending on the significance of a Wald test
compared to a threshold a. The correlation between two
significant SNPs, due to linkage disequilibrium, is computed
through the Pearson’s correlation coefficient r and if two
significant SNPs are strongly correlated ðjr j > 0:89Þ, only
the most significant is kept. Finally, the most significant
variant among selected SNPs is kept in the final model
and steps are repeated until no association is significant6
(Figure 1).
In both approaches, we control the Family Wise Error Rate
(FWER), representing the percentage of datasets where at
least one variant is selected under H0, by correcting the nom-
inal a by the number of tests performed (Sidak correction)
corresponding to the number of polymorphic SNPs consid-
ered Nt (Figure 1). The FWER was set to 20% (with a pre-
diction interval for 200 datasets equal to [14.5–25.5]) for an
exploratory analysis. The prediction interval determined
when to adjust a to control the FWER under H0.
Simulated designs and analysis scenarios
We simulated a phase I study corresponding to the motivat-
ing example, including 78 subjects (N1) receiving eight dif-
ferent single doses (5, 10, 20, 50, 100, 200, 400, or 800
units, for respectively 6, 6, 24, 12, 12, 6, 6, and 6 subjects
per dose) and sampled 16 times. Three designs of phase II
study were simulated. They included 306 subjects (N2),
receiving three doses (20, 50, or 100 units, 102 subjects
per dose), sampled at steady state. Two phase II studies
included three samples per subject, optimized using the
PFIM software18 to ensure a reasonable precision of CL
estimates. The last sampling time was limited to 24 hours
in one, while a late sample was allowed after the last dose
administration in the other. The third study included only
one trough concentration (24 hours). We considered four
analysis scenarios (Figure 1), three combining the phase I
and one of the phase II study (respectively, SPI/II3s.24h,
SPI/II3s.96h, and SPI/II1s.24h), and one, for comparison, with
only the phase I subjects (SPI).
We also investigated the impact of a higher variability on
phenotype on the results. For this, we simulated the same
four scenarios increasing the IIV on CL to 60% (instead of
25% in previous settings).
Evaluation
For each analysis scenario, 200 datasets were simulated
under H0 and H1.
The ability of the designs to estimate the population and
individual parameters under H0 was first evaluated through
estimation bias and g-shrinkage (see details in Supple-
mentary Material, Supplementary Figures S5–S6).
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Under H1 we evaluated the performance of each scenario
in terms of true and false positive counts (TP and FP) and
rates (TPR, the proportion of TP detected among the
causal variants; and FPR, the proportion of FP detected
among all potential false associations) for parameter CL, as
well as the probability to detect genetic variants. Assuming
that SNPs located on genes coded for metabolism
enzymes and transporters affect mostly the drug distribu-
tion and elimination, we also applied association tests on
Q, the intercompartmental clearance, and V2, the periph-
eral volume, separately. Any variants associated to Q and
V2 were counted as false positives. The central volume V1
was not considered because it had no random effects.
We also evaluated the loss of genetic signal between
simulated and estimated individual clearances, comparing
slopes b of univariate linear regressions on log CLsimið Þ or
Figure 1 Workflow of the simulation study divided in the simulation (blue box) and analysis part (red box). At 0.5, 1, 1.5, 2, 3, 4, 6, 8,
12, 16, 24, 48, 72, 96, 120, and 192 hours. CLsimi , simulated individual clearance i51; . . . ;N5N11N2ð Þ; EBECLi , empirical Bayes esti-
mate of clearance; H0, null scenarios; H1, alternative scenarios; FWER, family-wise error rate; N1, number of subjects from the phase I
study; N2, number of subjects from the phase II study; Nt , number of polymorphic SNP to analyze; p, P value; r , correlation coefficient
between variants; RGC , genetic component of the interindividual variability; SNPik , single nucleotide polymorphism k51; . . . ;Ntð Þ; a,
type I error per test; bk , effect size coefficient; n, Lasso tuning parameter.
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log EBECLi
 
for each causal variant. A relative deviation of
the genetic signal RDsignal was computed as follows:
RDsignal %ð Þ5
bEBECLi2bCLsimi
bCLsimi
3100 (3)
RDsignal quantifies the departure of the estimated genetic
signal (bEBECLi ) from the one simulated (bCLsimi , see details
in Supplementary Material).
RESULTS
Control of FWER under H0
The Lasso and stepwise procedure methods both tended to
be too conservative, as the FWER was lower than
expected in some scenarios (Table 2). After an empirical
correction by increasing the type I error per SNP a, FWER
was properly controlled around 20%. This correction was
applied in the corresponding simulation under H1. Previous
simulations suggested that this decrease in FWER is influ-
enced by correlations between polymorphisms.6
Detection of genetic effects
Under H1 the TPR (Figure 2, top left) was higher in scenar-
ios including phase II data (from 22 to 32%) compared to
scenario with only phase I data (SPI, 4%) and was the
highest in scenario SPI/II3s.96h. The FPR was lowest (0.2%)
in scenario SPI, where a limited number of SNPs was
selected, and only slightly higher in scenarios including
phase II data, ranging from 0.6 to 0.8% for both methods.
Very few TP were effectively detected in scenario SPI
(around 44 for both methods) where the number of subjects
was limited (N1578) (Supplementary Tables S2–S3). By
adding more subjects (N25 306) to the analysis, the num-
ber of TP increased sharply. Scenario SPI/II3s.96h allowed
detecting the largest number of TP (380 or more), while in
SPI/II3s.24h around 326 TP were detected. In SPI/II1s.24h the
number of TP was lower (around 270 TP), but remained
much higher than scenario SPI with only phase I data. In
the same way, the number of FP increased when including
phase II data in the analysis, but to a much lesser extent.
With only phase I data, the probability to detect at least
one genetic variant on CL was low (Figure 2, bottom left),
around 20% (SPI). This probability decreased quickly when
trying to detect more polymorphisms and reached 0 for
three variants or more. Adding phase II data to the analysis
increased the probability to detect at least one variant
about 85% in scenario SPI/II1s.24h, and up to 95% in sce-
nario SPI/II3s.96h. Scenarios including phase II data showed
good detection of one to three SNPs and SPI/II3s.96h had
always the higher detection. This shows that the major
determinant of power is the number of subjects, and that
optimizing the design for more informativeness can bring a
smaller further improvement. The low probability to detect
four SNPs or more ( 4%) in scenarios combining phase I
and phase II data can be explained by those variants hav-
ing a very weak impact; polymorphisms only explaining 1,
2, or 3% of the variability of CL.
In Supplementary Table S4, the TPR was computed
separately for each causal SNP. The variants associated
with the lowest RGC had low TPR, close to the FPR. Thus,
the signal associated with these variants was close to the
noise created by the noncausal variants.
Shrinkage
Two g-shrinkage estimates were computed using a metric
proposed by Bertrand et al.4 based on estimated variances,
with respect to the estimate of x^2 in the dataset; one over
the g^ i from phase I subjects and one over the g^ i from
phase II subjects (Figure 3). The g-shrinkage for phase I
Table 2 Empirical estimates of family-wise error rate under H0 for both association tests
FWER (%)
Method SPI SPI/II3s.96h SPI/II3s.24h SPI/II1s.24h
Lasso Without correctiona 14 17.5 21.5 13.5
Stepwise procedure Without correctiona 20 18.5 22.5 15.5
Lasso After empirical correctionb 20 19.5 21.5 19.5
Stepwise procedure After empirical correctionb 20 20.5 22.5 20.5
The 95% prediction interval around 20 for 200 simulated datasets is [14.5–25.5].
aSet of empirical family-wise error rates (FWER) obtained without correction.
bSet of empirical FWER obtained after correction of type I error per tests.
Table 1 Population values (m) and interindividual variability (x) for the model
parameters of drug S used in the simulation study
Parameters m x (%)
Fa ImaxF 0.8 32.9
D50F 41.7
FRACb EmaxFRAC 0.45 –
D50FRAC 18.6
Tlag1 0.401 35.1
Tk0 1.59 31.6
Tlag2 22.7 –
Ka 0.203 –
V1 1520 –
Q 147 89.9
V2 2130 44.2
CL 94.9 25.1
rslope (%) 20 –
F, bioavailability; FRAC, fraction of dose; Tk0, zero-order absorption dura-
tion; Tlag1, lag time of zero order absorption; Ka, first order absorption con-
stant rate; Tlag2, lag time of first order absorption; V1, central compartment
volume; V2, peripheral compartment volume; Q, intercompartmental clear-
ance; CL, linear elimination clearance.
aFor doses < 20 units F51, for doses  20 units F512 ImaxF dose 2 20ð ÞD50F 1 dose 2 20 ,
where dose is the amount administered.
bFRAC5 EmaxFRAC doseD50FRAC 1 dose
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subjects was low (median5 23%) thanks to the large num-
ber of observations per subject. A large range of g-
shrinkage estimates for phase II data was observed across
analysis scenarios, but was below 50% in scenario SPI/
II3s.96h.
Loss of signal
RDsignal was always negative for the six SNPs, indicating
that part of the signal was lost during the estimation step
(Figure 4, top). This loss was smaller in the scenario with
phase I data alone (SPI) than in scenarios combining
phase I and phase II data. In each scenario the signal loss
was of the same magnitude for the six SNPs, regardless of
the value of associated RGC. For phase I data (Figure 4,
bottom), the loss was of a constant magnitude across sce-
narios (median5230%). For phase II data, in the most
informative scenario (SPI/II3s.96h), the loss was of a similar
magnitude (median5241%) than the loss in phase I data,
where subjects were extensively sampled. The loss was
higher in scenario SPI/II3s.24h (median5256%), and even
more when only one time was sampled (SPI/II1s.24h,
median5270%).
The signal loss and g-shrinkage values changed accord-
ingly across phase II scenarios, while the probability of
detection changed in the opposite direction.
Influence of the phenotype variance
Increasing IIV for the CL parameter to 60% led to a sharp
increase in the number of TP (Supplementary Tables S5–
S6), resulting in higher TPR and higher probabilities to
detect the causal variants (Figure 2, right), compared to
when individual CLs were simulated with a moderate IIV.
This higher number of TP is explained first and foremost by
the increase in simulated effect sizes, which depended on
the variance of interindividual random effects on CL due to
nongenetic sources (Eq. 2). A second consequence of the
larger IIV was that the estimated g-shrinkages became
much smaller. Lower g-shrinkages resulted in lower signal
losses in all scenarios for phase I and phase II data (Sup-
plementary Figures S7–S8), which again favored a higher
probability to detect the genetic effects.
Figure 2 True positive rate (TPR) vs. false positive rate (FPR) under H1 (top) and probability estimates (points) and 95% confidence
interval (bars) to detect at least x variants explaining the interindividual variability of CL ðx51; . . . ; 6Þ under H1 (bottom) for main sce-
narios simulated with IIVCL525% (left) or modified scenarios simulated with IIVCL5 60% (right). Different symbols are used for each
scenario, and colors denote the Lasso (gray) and the stepwise procedure (light blue).
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Figure 3 Distribution of the g-shrinkages on clearance for subjects in the phase I dataset (blue) and for subjects in the phase II dataset
(brown), for each main scenario simulated under H0 with IIVCL5 25%.
Figure 4 Boxplots showing the loss of the signal for genetic effect in the overall population (top), as well as separately for the phase I
data (blue borders) and for the phase II data (brown borders) (bottom). A boxplot is shown separately for each main scenario simulated
under H1 with IIVCL5 25% as a function of increasing RGC (boxplots color).
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DISCUSSION
In this work we show and evaluate practical designs to
combine data from studies occurring in phase I and II of a
drug development. We assess through a simulation study,
inspired by a real example, the probability to detect genetic
variants and the influence of the phase II study design. We
considered phenotypes estimated by NLMEM, which can
handle the analysis of heterogeneous data involving
sparsely sampled subjects.
Genetic variants are unbalanced and so the amount of
information they provide is directly related to the variant
allele frequency and the study sample size. On the other
hand, PK information depends also on the number and
times of sampling which drives the precision of the PK
model parameter estimates. A limited number of samples,
as in phase II studies, may lead to missing a true associa-
tion when EBE are used as phenotypes.9 Savic and Karls-
son suggested a more extensive use of the likelihood ratio
test (LRT) for covariate selection when g-shrinkage is large,
but Combes et al. showed that the power to detect a cova-
riate effect is the same with an LRT or a simple correlation
test on EBE.19
The effect of sample size can be distinctly observed in
our simulations. In the context of phase I studies, where
the number of subjects is limited, the probability to detect
the genetic effects was low, in line with our previous
results.6 The combined analysis of phase I and phase II
data allowed a marked improvement in this detection proba-
bility, irrespective of the phase II study design. By modifying
the design of the phase II data, we highlighted a direct link
between g-shrinkage, loss of genetic signal, and probability
to detect genetic variants. Our results showed that poor PK
information due to the phase II study design results in
higher g-shrinkage, which increases the loss of genetic sig-
nal at the estimation step and translates to a lower proba-
bility to detect genetic variants. The dilution of the
individual information by adding subjects with sparse
designs to subjects with rich designs increases, as
expected, the loss of genetic signal. But this is accompa-
nied with a sharp increase in detection power thanks to a
larger sample size. g-shrinkage may also modify the EBE–
EBE relationship, falsely inducing or masking correlations
between model parameters.9 This could result in an
increased number of false positives associated with other
parameters than CL, although in our simulations the num-
ber of FP on CL, V2, and Q remained of a similar magni-
tude across scenarios (Supplementary Table S3), showing
no systematic effect.
We assume homogeneity of the PK between subjects
simulated for the phase I and the phase II study. In prac-
tice, healthy volunteers are often included in phase I, while
phase II studies focus on patients. A difference in typical
values, for example of CL, between the two populations
should not impact the detection power by combination of
data, as the association tests use the phenotype variance,
provided that the genetic effect is the same and that the
model accounts for the systematic difference between
clearances. It is more difficult to predict what would happen
if the variability of clearance is different in the two popula-
tions, as the magnitude of the shrinkage in each subpopu-
lation could affect the signal detection. When the
assumption that the two populations are similar breaks
down, we would suggest instead to combine rich and
sparse data within the phase II study. Pharmacogenetic
studies including a large number of subjects combining
sparse and rich designs have already been published,20,21
showing that the combination of different sampling designs
is feasible within the same study to assure more
homogeneity.
Situations where pharmacogenetic analyses in PK stud-
ies are recommended are described by health authorities.22
In our work, we simulated a blinded pharmacogenetic anal-
ysis, exploring a large number of genetic markers. In real
applications, other considerations than the statistical signifi-
cance of genetic variants such as their physiological and
clinical relevance could be factored in the analysis and its
interpretation. Lehr et al.23 proposed in their stepwise
procedure to select only significant polymorphisms having
a physiologic relevance in the final model, and the same
constraint could be integrated in penalized regression
approaches. The probability to detect genetic variants could
also be increased through the targeted inclusion of subjects
for a few polymorphisms of interest, but this approach
requires hypotheses on which polymorphisms to test, with
a risk to miss important associations. We focused in this
work on PK variability, which is a part of the variability in
drug response. But the conclusions from the simulation
study could be extended to pharmacodynamics. A previous
survey indicated that most pharmacogenetic analyses in
clinical PK studies used a phenotype estimated by NCA
and furthermore included a limited number of subjects
(fewer than 50 subjects in two-thirds).6 Authorities in fact
recommend studying pharmacogenetics in phase I,22 where
the number of subjects is limited. Our work shows that
such analyses do not have the power to detect polymor-
phisms efficiently, but can generate hypotheses to assess
in later studies. A recent simulation work24 studied the sam-
ple size required to detect a binary covariate. They con-
cluded that around 60 subjects combining rich or sparse
designs was sufficient to detect the covariate with at least
80% power. Again, our simulations showed that genetic
covariates require higher sample sizes because they are
highly unbalanced.
In the first series of simulations a moderate IIV on CL
(25%) was used, resulting in a low impact of the genetics
on PK, since overall 30% of the moderate CL variability
was explained by genetic variants. This setting represented
a realistic case to challenge the detection of genetic var-
iants through modeling. We also evaluated the same sce-
narios with a higher IIV for CL, set to 60%. The g-shrinkage
was much lower, as a higher IIV downweighs the popula-
tion prior in the combined criterion used to compute EBE.
This decrease in CL g-shrinkages resulted in lower signal
loss because of the direct relationship between the two.
Associated with larger simulated effect sizes, the number of
TP and the probability to detect genetic variants increased
in these scenarios. The effect of g-shrinkage on the proba-
bility to detect genetic effects in these simulations was
higher than the one we observed with the main settings,
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because the decrease of g-shrinkage was associated with
a sharp increase in the number of TP. This shows that our
conclusions do not depend on the level of IIV.
This simulation study also confirms the results of our pre-
vious work concerning the relative performance of the dif-
ferent association methods.6 The penalized regression
method Lasso and the stepwise procedure showed a simi-
lar probability to detect genetic variants in all scenarios.
However, Lasso is a slightly more complex method that
requires computing the penalty in a first step before testing
the associations. In this work we assessed methods to
detect genetic effects on EBE, after an initial fit. An algo-
rithm proposed by Lehr et al.23 uses univariate regressions
to select variants to test in the PK model through LRT. This
approach is easy to implement but runtimes depend on the
number of iterations leading to the full covariates model. An
alternative is to use an integrated approach where effect
sizes are estimated and significant variants selected using
a penalized regression in the same step17; this showed
similar performance as the stepwise procedure proposed
by Lehr et al., but with longer computing times.17 The
results for the two other penalized regression methods
tested in the previous work, ridge regression and Hyper-
Lasso, were similar (Supplementary Tables S7–S9, Fig-
ure S9). None of the methods detected the six SNPs
simultaneously, as three of the polymorphisms only
explained 1 to 3% of the clearance variability, making them
difficult to detect. Because association methods relate the
polymorphisms to the phenotype variance, we fixed the var-
iance explained by the causal variants (through the param-
eter RGC) and computed the effect sizes as a function of
their allelic frequencies. For a given RGC an infrequent poly-
morphism was therefore associated with higher effect sizes.
This reflects that a clinically relevant polymorphism (with a
high impact on PK), present in few subjects because of its
low frequency, will explain a limited proportion of the pheno-
type variance. Detecting such polymorphisms is crucial to
identify subpopulations at risk but require much larger sam-
ple sizes, as in genome-wide studies.25 As an example, the
rs3918290 polymorphism from gene DPYD has a frequency
lower than 1%, but results in a deficient dihydropyrimidine
dehydrogenase activity associated with a 40% decrease of
the maximum conversion capacity of the chemotherapeutic
drug 5-fluorouracil,26 resulting in severe toxicities.
The power to detect polymorphisms is also closely
related to the type I error chosen for the analysis. In a con-
text of exploratory analyses, we fixed the global type I error
to 20%. But using the Sidak correction the significance
thresholds were finally lower than 0.1% for each test, so
that only strong effects of causal variants will be detected,
and our simulations show that polymorphisms explaining a
limited part of the phenotype variance are not detected.
Approaches based on FWER and corrections such as Bon-
ferroni or Sidak are easy to implement but are conservative
and may reduce the power of analyses, but limit the num-
ber of polymorphisms to test in later confirmatory trials. In
practice, other corrections for type I error could be consid-
ered, as permutation methods that are more time-
consuming but less conservative.
Although this correction was conservative and was cali-
brated under H0 to control the FWER, the proportion of FP
under H1 among selected variants was higher than the
expected 20%. This could reflect the correlations between
polymorphisms we simulated.
To make more specific recommendations for study
designs is difficult because it is closely related to the devel-
oped drug. In our simulations a late sample allowed larger
information on the elimination phase to estimate CL. This
result can be generalized to pharmacogenetic studies
involving clearance and drugs with a long half-life. Taking a
late sample requires suspending treatment long enough to
observe a decrease in concentrations, which may not be
possible in patients from phase II trials.
In any case, it is essential that the sampling protocol,
although limited, is as informative as possible to minimize
the estimation error and shrinkage in individual parameters
estimation. The detection of genetic polymorphisms could
highly benefit from the use of larger sample sizes through
combined analysis and optimized design.18,27
In conclusion, this work confirmed the very limited likeli-
hood that weak genetic effects can be detected in a typical
phase I study, due to the small sample size. Such studies
have to be considered only as hypothesis-generating.28 On
the basis of our results in terms of detection probability
when analyzing together data from phase I and phase II
studies, we claim that phase II is the best moment to iden-
tify the impact of genetic variants on drug response. It
would be less efficient to start the study of the pharmacoge-
netics of a new drug in phase III trials or in postmarketing,
because these take place too late in drug development29
and the new treatment could be administered in nonres-
ponders or expose subjects to high toxicities. Furthermore,
genetic subpopulations can be better targeted and poten-
tially some subjects excluded from the study to increase the
efficacy and reduce the risk of toxicity of the drug in these
phase III studies.
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